The effects on cancer cell proliferation and differentiation mediated by Peroxisome Proliferator-Activated Receptors (PPARs) were widely studied, with pleiotropic outcomes in different cancer models and experimental conditions. Interestingly, relatively few studies and preclinical evidences report the potential antitumor activity of PPAR antagonists. This review focuses on recent findings about the antitumor in vitro and in vivo effects observed for compounds able to inhibit the three PPAR subtypes in different tumor models, providing a rationale for the use of PPAR antagonists in the treatment of tumors expressing the corresponding receptors.
The anticancer potential of Peroxisome Proliferator-Activated Receptor antagonists
Laura De Lellis;Serena Veschi;Rosa Amoroso
;Alessandro Cama
;Alessandra Ammazzalorso
2018-01-01
Abstract
The effects on cancer cell proliferation and differentiation mediated by Peroxisome Proliferator-Activated Receptors (PPARs) were widely studied, with pleiotropic outcomes in different cancer models and experimental conditions. Interestingly, relatively few studies and preclinical evidences report the potential antitumor activity of PPAR antagonists. This review focuses on recent findings about the antitumor in vitro and in vivo effects observed for compounds able to inhibit the three PPAR subtypes in different tumor models, providing a rationale for the use of PPAR antagonists in the treatment of tumors expressing the corresponding receptors.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
